ArticlePloS one2009
Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 57 citations in OpenAlex.
- In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.PLoS pathogens · 2012Trial
- Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny.Nature communications · 2025Article
- Humanized Mice for Studies of HIV-1 Persistence and Elimination.Pathogens (Basel, Switzerland) · 2023Review
- Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects.Cell communication and signaling : CCS · 2023Review
- Advancing cell-based cancer immunotherapy through stem cell engineering.Cell stem cell · 2023Review
- Promising Stem Cell therapy in the Management of HIV and AIDS: A Narrative Review.Biologics : targets & therapy · 2022Review
- Review
- Article
- Humanized Mice for the Evaluation of Novel HIV-1 Therapies.Frontiers in immunology · 2021Review
- Mouse models in hematopoietic stem cell gene therapy and genome editing.Biochemical pharmacology · 2020Review
- Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Monitoring HIV DNA and cellular activation markers in HIV-infected humanized mice under cART.Virology journal · 2018Article
- Approaches for generation of anti-leukemia specific T cells.Cell regeneration (London, England) · 2018Review
- The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer.Frontiers in immunology · 2018Review
- In Vivo Murine-Matured Human CD3Molecular therapy. Methods & clinical development · 2017Article
- Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy.Human vaccines & immunotherapeutics · 2017Article
- Chimeric antigen receptor engineered stem cells: a novel HIV therapy.Immunotherapy · 2017Review
- Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.The Journal of clinical investigation · 2017Article
- Engineering HIV-Specific Immunity with Chimeric Antigen Receptors.AIDS patient care and STDs · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a desperate need for effective therapies to fight chronic viral infections. The immune response is normally fastidious at controlling the majority of viral infections and a therapeutic strategy aimed at reestablishing immune control represents a potentially powerful approach towards treating persistent viral infections. We examined the potential of genetically programming human hematopoietic stem cells to generate mature CD8+ cytotoxic T lymphocytes that express a molecularly cloned, "transgenic" human anti-HIV T cell receptor (TCR). Anti-HIV TCR transduction of human hematopoietic stem cells directed the maturation of a large population of polyfunctional, HIV-specific CD8+ cells capable of recognizing and killing viral antigen-presenting cells. Thus, through this proof-of-concept we propose that genetic engineering of human hematopoietic stem cells will allow the tailoring of effector T cell responses to fight HIV infection or other diseases that are characterized by the loss of immune control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.